Monitor for the filing of the registration statement required for the equity line and any conversion notices on the convertible notes. The extreme dilution potential (equity line up to 10x market cap) suggests significant downward pressure on the stock. Watch for stockholder approval requests regarding the Nasdaq Exchange Cap. The 6-month lock-up on variable-rate transactions in the equity purchase agreement may limit near-term additional toxic financing.
Price Chart
Executive Summary
Healthcare Triangle, Inc. (HCTI) entered into two capital-raising agreements on June 12, 2026: (1) a securities purchase agreement for the sale of Original Issue Discount Senior Convertible Promissory Notes (aggregate principal amount undisclosed, due December 12, 2026) with a 15% OID and a conversion price set at 85% of VWAP (floor $0.452/share), and (2) an equity purchase agreement with Hudson Global Ventures, LLC for up to $50 million of common stock via a variable-rate equity line (purchase price at 94% of the lowest traded price). The convertible note carries a 10% default interest rate, a 150% mandatory default amount, and a 4.99% beneficial ownership blocker. The equity line requires an effective registration statement, has a 36-month commitment period, and includes a 4.99% beneficial ownership limitation. These transactions are highly dilutive to existing common shareholders and signal severe financial distress given the company's $5M market cap.
Key Facts
- Company entered into a Securities Purchase Agreement for Original Issue Discount Senior Convertible Promissory Notes due December 12, 2026 with a 15% original issue discount.
- Conversion price is 85% of the 3-day VWAP prior to conversion, with a floor price of $0.452 per share.
- Company entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC for up to $50,000,000 of common stock.
- Equity line purchase price is the lesser of 94% of the 3-day average of the 3 lowest traded prices or 94% of the lowest traded price during the valuation period.
- Equity line has a 36-month commitment period and requires an effective registration statement for resale.
- Both transactions include a 4.99% beneficial ownership limitation for the investor.
- Convertible note has a mandatory default amount of 150% of outstanding principal plus accrued interest.
- Company's market capitalization is approximately $5 million, making the $50 million equity line commitment extremely dilutive.
- The convertible note contains a 10% default interest rate and requires stockholder approval for issuances exceeding the Nasdaq Exchange Cap.
Financial Impact
Up to $50 million in potential equity issuance via equity line (approximately 10x current market cap), plus an undisclosed amount of convertible notes with a 15% OID and conversion at 85% of VWAP. The $50 million equity line alone represents extreme dilution relative to the $5M market cap.
Risk Factors
- Extreme dilution from up to $50 million in equity line issuances relative to $5M market cap
- Convertible note conversion at 85% of VWAP with a floor of $0.452 creates persistent selling pressure
- 15% original issue discount on notes means immediate economic loss for the company
- 150% mandatory default amount creates severe penalty if company defaults
- Equity line requires effective registration statement; any delay could trigger penalties
- Company may struggle to meet Nasdaq listing requirements given financial distress
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-068871 |
| Document: ea029478001ex10-2.htm | 0001213900-26-068871 |
| Document: ea029478001ex4-1.htm | 0001213900-26-068871 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEF 14A | $0.3820 | awaiting T+20 | — | $6.69 (−1651.54%) |
Oct 2, 2026 24d ago | 8-K | $0.6069 | awaiting T+20 | — | $6.69 (−1002.47%) |
Oct 1, 2026 26d ago | EFFECT | $0.7016 | awaiting T+20 | — | $6.69 (−853.66%) |
Aug 13, 2026 10w ago | Press Release | $1.73 $0.7457 | ▲ +56.90% | ▲ +55.15% | $6.69 (−286.76%) |
Jul 29, 2026 12w ago | 8-K | $1.56 $0.8683 | ▲ +44.34% | ▲ +49.36% | $6.69 (−328.90%) |
Jul 27, 2026 13w ago | Press Release | $1.70 $0.8446 | ▼ −50.32% | ▼ −53.62% | $6.69 (+293.58%) |
Jul 16, 2026 14w ago | EFFECT | $1.89 $1.73 | ▲ +8.47% | ▲ +12.08% | $6.69 (−254.02%) |
Jun 26, 2026 17w ago | 8-K | $1.88 $1.62 | ▲ +13.83% | ▲ +13.55% | $6.69 (−255.90%) |
Jun 15, 2026 19w ago | 8-K | $2.30 $1.74 | ▲ +24.35% | ▲ +24.55% | $6.69 (−190.91%) |
Apr 16, 2026 27w ago | 10-K/A | $2.47 $2.28 | ▲ +7.69% | ▲ +13.06% | $6.69 (−170.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers